Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
- Trial name
- NCT00990314
- Testing
- Beraprost Sodium Modified Release
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 31 people
- Sponsor
- Lung Biotechnology PBC
Idiopathic Pulmonary Arterial Hypertension
Empagliflozin in Pulmonary Arterial Hypertension
The aim of the study is to determine whether conducting a randomized placebo-controlled clinical trial is feasible, safe for the patient and whether the treatment is well tolerated in patients with idiopathic pulmonary arterial…
- Trial name
- Emphower PoC (NCT05493371)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension
Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
The main purpose of this clinical trial is to examine the feasibility and effects of fulvestrant in post-menopausal women with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated.
- Trial name
- ERA-PAH (NCT02911844)
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension…
- Trial name
- UMBRELLA (NCT03422328)
- Testing
- macitentan
- Where
- 34 sites in Belarus, Belgium and 5 more
- Volunteers
- 151 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Air Pollution
The Risk of Adverse Pregnancy Outcomes for Long-term Exposure to Air Pollution in Pregnant Patients With Pulmonary Hypertension
With economic development and rapid urbanization, air pollution has become an increasingly severe public health concern. The risk of adverse pregnancy outcomes is significantly elevated for pregnant women complicated by pulmonary…
- Conditions
- Pulmonary Arterial Hypertension, Air Pollution, Maternal Outcome
- Trial name
- NCT07164157
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Wei Huang
Pulmonary Arterial Hypertension
Safety, Tolerability and Pharmacokinetics of L608 in Healthy Adults
This is a Phase I, randomized, double-blinded, placebo-controlled single ascending dose, sequential-group study to evaluate the safety, tolerability, and PK of single ascending doses of L608 inhalation in healthy volunteers.
- Trial name
- NCT05938946
- Testing
- L608 Inhalation Solution
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Sickle Cell Disease
Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.
pulmonary arterial hypertension (PAH) has been reported with a prevalence of approximately 30% in adult sickle cell disease (SCD) patients, with an increased mortality in SCD patients with PAH, compared with those without PAH.
- Trial name
- SAPOTILLE (NCT03368261)
- Testing
- HTAP/ clinical complications in the sickle cell disease
- Where
- Martinique
- Volunteers
- 185 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Pulmonary Arterial Hypertension
BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension
The study is a single center randomised, double-blind, placebo-controlled crossover study to assess the effects of beetroot juice in patients with pulmonary arterial hypertension.
- Trial name
- BEET-PAH (NCT02000856)
- Testing
- Beetroot juice
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Uppsala University
Pulmonary Arterial Hypertension
Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
Study Rationale:There is recent evidence that HIV protease inhibitors (HIV-PI) can improve pulmonary hemodynamics in experimental models of pulmonary arterial hypertension (PAH).
- Trial name
- NCT02023450
- Testing
- saquinavir and ritonavir
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Scleroderma, Pulmonary Artery Hypertension
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure).
- Trial name
- CALIPSO (NCT04610788)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
Pulmonary Artery Hypertension, Congenital Heart Disease
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers.
- Conditions
- Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
- Trial name
- NCT03152773
- Testing
- MRI Heart guidewire catheterization
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Hypertension
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen…
- Trial name
- NCT07604805
- Testing
- Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital
Pulmonary Arterial Hypertension
Patient Reported Outcomes in Pulmonary Arterial Hypertension
Develop a brief, new, patient reported outcome instrument that is valid for use in clinical practice and clinical trials.
- Trial name
- PROPAH (NCT01792622)
- Testing
- Interview, Questionnaire
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Frailty
Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension
The purpose of the study is to learn more about how low-resistance training impacts frailty and the quality of life of people with pulmonary arterial hypertension (PAH).
- Trial name
- RESIST-PH (NCT06543745)
- Testing
- Low-Resistance Training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pulmonary
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension.
- Trial name
- NCT01824290
- Testing
- Tadalafil, ERA as specific PAH treatment
- Where
- 43 sites in United States, Austria and 12 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension (PAH), Quality of Life
Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension
This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Quality of Life, Patients Reported Outcomes
- Trial name
- NCT07570615
- Testing
- Questionnaire Assessment
- Volunteers
- 300 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Aortic Valve Stenosis, Pulmonary Hypertension
Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population.
- Trial name
- HTP-TAVI (NCT04008550)
- Testing
- Right Heart Catheterization
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer